Welcome to our dedicated page for CERC news (Ticker: CERC), a resource for investors and traders seeking the latest updates and insights on CERC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CERC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CERC's position in the market.
Cerecor Inc. (NASDAQ: CERC) has expanded its agreement with Kyowa Kirin Co., securing exclusive worldwide rights to develop and commercialize CERC-002, a monoclonal antibody meant for various indications, including severe pediatric inflammatory bowel disease and COVID-19 ARDS. The deal gives Cerecor the rights in the U.S., Europe, and worldwide, while Kyowa Kirin can retain Japanese rights. Cerecor will make an upfront payment and additional milestone payments based on regulatory achievements.
Cerecor Inc. (NASDAQ: CERC) announced positive outcomes from its Phase 2 trial of CERC-002, showing significant reductions in respiratory failure and mortality among COVID-19 ARDS patients. The company reported a financial boost with $18.9M cash as of December 31, 2020, and raised an additional $37.6M in January 2021. Cerecor aims for significant 2021 milestones, including potential FDA Breakthrough Therapy and Fast Track Designations for CERC-002, while advancing its pipeline across immunology and oncology.
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical firm focused on rare and orphan diseases, announces that CEO Michael F. Cola will present at two virtual conferences. The H.C. Wainwright Global Life Sciences Conference will occur on March 9-10, 2021, with a pre-recorded presentation available on March 9 at 7:00 AM ET. The Oppenheimer 31st Annual Healthcare Conference is scheduled for March 17, 2021, at 8:00 AM ET. These presentations can be accessed via the Investors section of Cerecor's website. The company is advancing a clinical pipeline addressing significant unmet patient needs in rare diseases.
Cerecor Inc. announced final efficacy data for CERC-002 from a Phase 2 trial in COVID-19 ARDS patients. The study met its primary endpoint, showing a statistically significant reduction in respiratory failure and mortality (p=0.044) at Day 28. Notably, patients over 60 exhibited the highest efficacy (p=0.042). An approximately 50% reduction in mortality was observed at both 28 and 60 days (22.5% vs 10.8%). CERC-002 was well-tolerated, with no serious adverse effects reported. Cerecor has applied for FDA Breakthrough Therapy and Fast Track Designations, aiming for Emergency Use Authorization.
Cerecor Inc. (NASDAQ:CERC) has appointed Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. Greenway brings over 20 years of experience in investment banking and finance, notably in life sciences. He succeeds Chris Sullivan, who will continue as Chief Accounting Officer. The board approved a grant of 500,000 stock options to Greenway, with specific vesting conditions. Cerecor is focused on developing treatments for rare diseases and has a robust pipeline including multiple candidates that have received orphan drug designations.
Cerecor Inc. (NASDAQ: CERC) has announced the underwriters' exercise of an option to purchase an additional 1,648,812 shares at $2.60 per share, raising total gross proceeds to approximately $40.7 million from its public offering. The funds are intended for general corporate purposes, including ongoing clinical development and administrative expenses. The offering followed an effective shelf registration statement filed with the SEC. Cerecor focuses on treatments for rare pediatric and orphan diseases, with several candidates in active development.
Cerecor Inc. (Nasdaq: CERC) has completed an underwritten offering of 12,323,077 shares at $2.60 each, raising approximately $33.6 million. A related offer of pre-funded warrants for 1,676,923 shares was made at a price of $2.599 each. The underwriters received a 30-day option to purchase an additional 2,100,000 shares. Proceeds will support ongoing clinical developments and general corporate purposes. The offering is registered under an effective shelf registration statement with the SEC.
Cerecor Inc. (CERC) announced a public offering of 12,323,077 common shares at $2.60 each, with an additional option for underwriters to purchase 2,100,000 shares. The offering aims to raise approximately $36.4 million for corporate purposes, primarily for ongoing clinical development of its pipeline targeting rare diseases. The offering will close around January 12, 2021. Cerecor's rare disease pipeline includes innovative therapies with several candidates, like CERC-002 for severe pediatric Crohn's disease and CERC-006 for lymphatic malformations.
Cerecor Inc. (Nasdaq: CERC) announced plans to offer common stock and pre-funded warrants in an underwritten public offering. The offering may include an additional 15% at the underwriters' discretion. Proceeds will support clinical development and general corporate purposes. Jefferies serves as the book-running manager, while Oppenheimer leads the offering. The securities are offered under an effective shelf registration statement with the SEC. Full details will be outlined in a prospectus supplement.
Cerecor Inc. (NASDAQ: CERC) announced results from a Phase 2 trial of CERC-002, an anti-LIGHT monoclonal antibody, for COVID-19 ARDS patients. The study showed a robust improvement in the proportion of patients alive and free from respiratory failure compared to placebo (OR = 2.62, p=0.059). In patients aged 60+, treatment increased the likelihood of avoiding respiratory failure (OR = 3.38, p=0.054). Mortality was reduced by approximately 50% (4 deaths on CERC-002 vs. 9 on placebo). The company plans to discuss these results with the FDA and explore further applications of CERC-002.
